Last
Update:
July 31, 2011
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
6th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
-
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Experience with non nucleoside reverse transcriptase inhibitors (NNRTIs):
failure, resistance and susceptibility
to etravirine
T. Franic, D. Quan, A. Gowers, et al
Poster
Abstract
POSTER
Persistence of antiretroviral regimens including raltegravir, maraviroc,
darunavir and/or etravirine in clinical practice
I. Castillo Romera, N. Trovato López, S. Plata Paniagua, et al
Poster
Abstract
POSTER
Experience with non nucleoside reverse transcriptase inhibitors (NNRTIs):
failure, resistance and susceptibility to
etravirine
T. Franic, D. Quan, A. Gowers, et al
Poster Abstract
The SENSE trial: final 48-week analysis of etravirine (ETR) versus efavirenz
(EFV) in treatment-naïve patients
J. Rockstroh, A. Streinu-Cerce, V. Pokrovsky, et al
Bioavailability of etravirine 200mg administered as a single 200-mg tablet
versus two 100-mg tablets in HIV-negative,
healthy volunteers
T. Kakuda, G. de Smedt, R. Leemans, et al
Etravirine penetration in cervicovaginal compartment exceed the median
inhibitory concentration in HIV-1
infected women
treated with etravirine-containing regimen (DIVA-02 study)
C. Clavel, G. Peytavin, R. Tubiana, et al
Population pharmacokinetics of etravirine in HIV-1-infected
treatment-experienced children and adolescents
(6-17 years): week
24 primary analysis of the phase II PIANO trial
T. Kakuda, B. Green, G. Morrish, et al
Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced
children and adolescents (6-17 years):
week 24 primary
analysis of the phase II PIANO study
G. Tudor-Williams, P. Cahn, K. Chokephaibulkit, et al
Etravirine resistance mutations among HIV-1 infected patients failing first
and second line treatment in Malian
cohort in West Africa
A.I. Maiga, D.B. Fofana, M. Cissé, et al
18th Conference on
Retroviruses and Opportunistic
Infections |
Therapeutic DRV
and ETR Concentrations in Cerebrospinal Fluid
B Best, S Letendre, D
Croteau, et al
PDF Poster
Abstract
POSTER
Slow Accumulation of Thymidine
Analog and ETR-associated Mutations in NNRTI-treated Children
with Virologic Failure
T Puthanakit, S Kerr, T Bunupuradah,
et al
PDF Poster
Abstract
POSTER
Predictors of Virologic Response to
ETR-based cART Regimens in a Large European Cohort of HIV-infected Patients
A Cozzi-Lepri, R Paredes,
A Phillips, et al
PDF Poster
Abstract
POSTER
Pharmacogenetics-based Population
Pharmacokinetic Analysis of ETV in HIV-1-infected Individuals
R Lubomirov, M Rotger, A
Fayet, et al
PDF Poster
Abstract
POSTER
Prevalence and
Predictors of RAM to ETV in Perinatally HIV-1-infected Children, 1998 to 2009
G Contreras, C Bell, G
Delbianco, et al
PDF Poster
Abstract
ARV for HIV
Prevention: DRV + Low-dose RTV and ETR Exposure in the Rectal Tissue and
Seminal Plasma
of Healthy Male Volunteers after Single and Multiple Dosing
K Brown,
K Patterson, S Jennings, N Shaheen
XVIII International AIDS
Conference
|
Drug-resistant genotyping to guide selection of etravirine, darunavir and
raltegravir in salvage therapy
for multi-drug-resistant cases improves outcomes
N. Miyazaki, S. Matsushita, T. Fujii, et al
PDF Poster
Abstract
POSTER
Duration of antiretroviral regimens including
Raltegravir, Maraviroc, Darunavir and/or Etravirine in
clinical practice
I. Castillo Romera, A. Ais Larisgoitia, V. Escudero Vilaplana, et al
PDF Poster
Abstract
POSTER
Efficacy, safety and tolerability of etravirine (ETR) as salvage therapy in
HIV-1-infected paediatric
patients in clinical practice
V. Briz, C. Palladino, M.L. Navarro, et al
PDF Poster
Abstract
A
phase IV, double blind, multi centre, randomised, placebo controlled, pilot
study to assess the
feasibility of switching individuals receiving efavirenz (EFV) with continuing
central nervous system (
CNS) adverse events (AE) to etravirine (ETR)
L. Waters, M. Fisher, A. Winston, et al
Abstract
Genotypic resistance to darunavir, tipranavir and etravirine in patients with
failure to two or more
ARV combinations in Mexico
E. Vidal-Laurencio, L. Cabrera-Ruiz, A. Flores-Gaxiola, et al
Abstract
"Switch-EE": randomized double-blind cross-over comparison of etravirine and
efavirenz - final
per-protocol analysis
from the Swiss HIV cohort (SHCS)
A. Nguyen, A. Calmy, B. Hirschel1, et al
Abstract
The SENSE trial: etravirine (ETR) shows fewer neuropsychiatric adverse events
than efavirenz (EFV) i
n treatment-naïve HIV-1 infected patients
B. Gazzard, G. Di Perri, H. Furrer, et al
Abstract
17th Conference on
Retroviruses and Opportunistic
Infections |
Improved Genotypic Algorithm for
Predicting Etravirine Susceptibility: Comprehensive List of
Mutations Identified Through Correlation with Matched Phenotype
M Haddad, E Stawiski, J
Benhamida,E Coakley
PDF Poster
Abstract
POSTER
Resistance Associated Mutations to
Etravirine in Antiretroviral-naïve Patients Infected with
Non-B HIV-1 Subtypes
A Maiga, D Descamps, L
Morand-Joubert, et al
PDF Poster
Abstract
POSTER
Lack of Interaction between
Etravirine and Raltegravir plus Darunavir/Ritonavir When Combined |
in Treatment-experienced Patients: A Substudy of the ANRS 139 TRIO Trial
A Barrail-Tran Y Yazdanpanah,
C Fagard, et al
PDF Poster
Abstract
Selection
in vitro of a Novel Etravirine Associated Resistance Mutation in B and
non-B HIV-1
Subtypes
E Asahchop, C Tremblay, B
Brenner, et al
Abstract
Bulk and
Clonal Resistance Analyses in Highly Experienced Patients Failing Raltegravir,
Etravirine,
and Darunavir/ritonavir Containing Regimen (ANRS 139 TRIO Trial)
B Roquebert, C Colin, A-M Taburet,
et al
Abstract
Ultradeep
Sequencing Refines Phenotypic Predictions to Darunavir, Etravirine, and Other
Protease
and Reverse Transcriptase Inhibitors in Heavily Pre-Treated Subjects Infected
with Multidrug Resistant
HIV-1
F Codoñer, C Pou, A Thielen
, et al
Abstract
12th European AIDS Conference
|
|
-
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Etravirine demonstrates a favourable safety and
tolerability profile:pooled 96-week results from t
he Phase III DUET trials
P-M Girard, B Grinsztejn, A Rachline, et al|
PDF Poster
PDF POSTER
Safety and pharmacokinetics of etravirine in pregnant
HIV-infected women
P Izurieta, TN akuda, A Clark, et al
PDF Poster
POSTER
Pharmacokinetic interaction between etravirine and
lopinavir/ritonavir in HIV-negative volunteers
M Schöller-Gyüre, TN Kakuda, James Witek, et al
PDF Poster
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Etravirine demonstrates a favourable safety and tolerability
profile versus placebo irrespective of hepatitis co-infection:
Week 96 analysis from the DUET trials
B Clotet, C Katlama, N Clumeck, et al
PDF Poster
POSTER
The economic impact of national particularities in the
healthcare system – calculation for hospital-related costs from
pooled DUET trials by German diagnosis-related groups
M Stoll ,V Donatz, C Corbett, S Martin
PDF Poster
POSTER
Cost-effectiveness of current treatment options in
treatment-resistant HIV/AIDS patients in the German setting
L Annemans, A Hill, E Smets, S Martin
PDF Poster
5th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
-
A
WEEK-IN-REVIEW-FEATURED REPORT
POSTER
Etravirine (ETR;
TMC125) demonstrates durable efficacy in treatment-experienced
patients in the DUET trials: pooled 96-week results
A. Mills, P. Cahn, J.-M. Molina, et al
PDF Poster
Abstract
POSTER
Long-term safety
profile of etravirine in treatment-experienced, HIV-1-infected patients:
pooled 96-week results from the phase III DUET trials
T. Campbell, B. Grinsztejn, J. Hartikainen, et al
PDF Poster
Abstract
POSTER
Clinical endpoints reduced through etravirine use in treatment-experienced,
HIV-1-infected
patients: pooled 96-week results from the phase III DUET trials
J. Eron, R. Haubrich, P. Reiss, et al
PDF Poster
Abstract
POSTER
Predicted susceptibility of etravirine in
HIV patients experiencing virological failure secondary
to nonnucleoside reverse transcriptase inhibitor resistance
E. Cordova, H. Mingrone, N. Porteiro, E. Loiza
PDF Poster
Abstract
Is there any
potential for first line etravirine use? Analysis from a large dataset of
ART-naïve
HIV infected
patients undergoing resistance test
M. Zaccarelli, A. Antinori, A. Cozzi-Lepri, et al
Abstract
Virological
efficacy of etravirine in multifailed patients: role of mutation score
S. Lo Caputo, A. Di Biagio, P. Meraviglia, et al
Abstract
Early detection
of virologic failure is associated with preserved etravirine activity
B. Taiwo, J. Idoko, S. Penugonda, et al
Abstract
16th Conference on
Retroviruses and Opportunistic
Infections |
-
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Factors Associated with Early Virological Response to Etravirine in
NNRTI-experienced
HIV-infected Patients
A-G Marcelin, P Flandre, D Descamps, et
al
PDF Poster
Abstract
-
POSTER
Pharmacokinetics and Dose
Selection of Etravirine in HIV-infected Children between 6 and 17
Years, Inclusive
C Königs, C
Feiterna-Sperling, S Esposito, et al
PDF Poster
Abstract
-
Defining the Upper and Lower Clinical Cutoffs for Etravirine in the
PhenoSense HIV Assay
E Coakley, C Chappe, J Benhamida, et al
Abstract
-
Profiling Etravirine Resistance in Ugandan Children with Extended
Failure of a NNRTI-inclusive Regimen as
First-line ART
A Kekitiinwa, D Friedman, E Coakley, et
al
Abstract
Ninth International Congress on Drug Therapy in HIV Infection
|
-
POSTER
Virological response with fully active etravirine after 48 weeks of treatment:
pooled results from the DUET-1
and DUET-2 trials
N Clumeck, B Clotet, M Johnson, et al
PDF Poster
-
POSTER
Reduction in AIDS-defining events/deaths with etravirine compared to
placebo: pooled DUET 48-week results
R Haubrich, J Eron, M Thompson, et al
PDF Poster
-
POSTER
Pharmacokinetics of Once-Daily Etravirine (ETR) Without and With Once-Daily
Darunavir/
Ritonavir (DRV/r) in Antiretroviral-Naïve HIV-1 Infected Adults
J Lalezari, E DeJesus, O Osiyemi, et al
PDF Poster
-
POSTER
Cost-minimisation analysis of the use of etravirine or raltegravir in
treatment-experienced HIV-1-infected patients
E Smets, S Martin
PDF Poster
-
POSTER
Safety and tolerability of etravirine in hepatitis B and/or C
co-infected patients in DUET-1 and DUET-2:
pooled 48-week results
B Clotet, C Katlama, A Lazzarin, et al
PDF Poster
-
POSTER
Switching from enfuvirtide to etravirine – efficacy results from the etravirine
early access programme
E Ribera, M Loutfy, E Florence, et al
PDF Poster
-
POSTER
Etravirine protects the activity of darunavir in the DUET trials
M Peeters, J Vingerhoets, L Tambuyzer, et al
PDF Poster
-
POSTER
Activity of etravirine on different HIV-1 subtypes: Week 48 data of the pooled
DUET trials and in-vitro
susceptibility in treatment-naïve patients
J Vingerhoets, H Azijn, L Tambuyzer, et al
PDF Poster
-
POSTER
Antiretroviral treatment use and HIV RNA suppression rates for 941 European
patients in the etravirine
early access programme
E Florence, S De Wit, A Castagna, et al
PDF Poster
-
POSTER
Durability of virologic response to etravirine is not affected by time to
reach
virologic response
A Mills, La Cotte, S Smith, et al
PDF Poster
-
POSTER
Effect of etravirine on cytochrome P450 isozymes assessed by the
Cooperstown
5+1 cocktail
M Schöller-Gyüre, TN Kakuda, T Stevens,et al
PDF Poster
-
POSTER
Reduction in AIDS-defining events/death with etravirine compared to
placebo:
pooled DUET 48-week results
R Haubrich, J Eron, M Thompson, et al
PDF Poster
-
POSTER
Pharmacokinetics and pharmacodynamics of etravirine in
treatment-experienced
HIV-1-infected patients: pooled 48-week results of DUET-1 and DUET-2
TN Kakuda, M Peeters, C Corbett, et al
PDF Poster
-
POSTER
Treatment Response among HIV Patients Co-enrolled in the Etravirine (ETR)
and Raltegravir (RAL) Expanded Access Programs (EAPs) at Kaiser Permanente
Kerrigan H, Towner W, Klein D, Follansbee S
PDF Poster
XVII International AIDS
Conference
|
-
A WEEK IN REVIEW FEATURED
REPORT
POSTER
Efficacy, Safety and Tolerability of Etravirine With and Without Darunavir
and/or Raltegravir in
Treatment-Experienced
Patients: Preliminary Analysis of TMC125-C214 Early Access Program
(EAP)
in the US
W Towner, Z Haigney, MG Sension, et al
PDF Poster
-
A WEEK IN REVIEW FEATURED
REPORT
POSTER
48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline
characteristics on virologic
response to etravirine
P Cahn, J-M Molina, W Towner, et al
PDF Poster
-
A WEEK IN REVIEW FEATURED
REPORT
POSTER
The impact of background regimen on virologic response to etravirine:
pooled 48-week analysis of
DUET-1 and DUET-2
G Di Perri, J Valdez Madruga, K Sathasivam et al
PDF Poster
-
POSTER
Impact of etravirine on hospitalizations and hospital-related
costs:48-week findings from pooled DUET trials
K Gebo, S Martin, C Corbett, G De Smedt
PDF Poster
 -
A WEEK IN REVIEW FEATURED
REPORT
POSTER
Analysis of US costs of full virologic suppression for treatment
experienced, HIV-infected patients in the DUET trials
S Martin, AM Hill
PDF Poster
-
POSTER
Bioavailability of the 100mg etravirine tablet dispersed in water and of
the 25mg pediatric tablet formulation
M Schöller-Gyüre, TN Kakuda, RM Van Solingen-Ristea, et al
PDF Poster
-
POSTER
Incidence and severity of nervous system and psychiatric events are
similar with etravirine versus placebo:
pooled 48-week
data from the Phase III DUET studies
C Katlama, T Campbell, M Schechter, et al
PDF Poster
-
A WEEK IN REVIEW FEATURED
REPORT
POSTER
The incidence of rash observed with the NNRTI etravirine in the Phase III
DUET trials using pooled 48-week data
A Mills, B Grinsztejn, C Katlama, et al
PDF Poster
-
A WEEK IN REVIEW FEATURED
REPORT
POSTER
Combined darunavir and
etravirine resistance analysis of the pooled DUET trials: when can we
spare the other
new classes?
R Haubrich, JM Schapiro, J Vingerhoets,et al
PDF Poster
-
POSTER
Pharmacokinetics of etravirine are not affected by sex, age, race,
treatment duration or use of enfuvirtide in
HIV-1-infected subjects
TN Kakuda, M Schöller-Gyüre, M Peeters, et al
PDF Poster
-
POSTER
Etravirine has no effect on fetal development in rats and rabbits
A Raoof, S Lachau-Durand, J Verbeeck ,et al
PDF Poster
-
Bioavailability of the 100mg etravirine tablet dispersed in water and of the
25mg pediatric tablet formulation
M.
Schöller-Gyüre, T.N. Kakuda, R.M. Van Solingen-Ristea, et al
Abstract
-
Etravirine associated mutations and NNRTI hypersensitizing mutations among
HIV-1 subtype-C
.infected
etravirine-
naïve South Indian patients failing therapy.
S. Saravanan, M. Vidya, P. Balakrishnan , et al
Abstract
-
Treatment experience with etravirine and optimised background regimen: 24 week
data from a single centre cohort
C.
Scott, R. Jogiya, A. Teague, et al
Abstract
-
Impact of TMC125 on hospitalizations and hospital related costs: 24-week
findings from pooled DUET trials
K.
Gebo, S. Martin, C. Corbett, G. De Smedt
Abstract
2008 International
HIV Drug Resistance Workshop
|
POSTER
Determination of phenotypic clinical cut-offs for etravirine (ETR): pooled Week
24
results of the DUET-1 and DUET-2 trials
M Peeters, S Nijs, J Vingerhoets, et al
PDF Poster
POSTER
Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR)
G Picchio, J Vingerhoets, N Parkin,
et al
PDF Poster
POSTER
An update of the list of NNRTI mutations associated with decreased virologic
response to
etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical
trial data
J Vingerhoets, M Peeters, H Azijn, et al
PDF Poster
17th Canadian Conference
on HIV/AIDS Research
|
9th International
Workshop on Clinical Pharmacology of HIV
|
A WEEK IN REVIEW FEATURED REPORT
POWERPOINT PRESENTATION
Emerging mutations in patients with virological failure on etravirine (ETR;
TMC125) in the
DUET-1 and DUET-2 clinical trials
L. Tambuyzer, J. Vingerhoets, H. Azijn, et al
Slide
Presentation
POWERPOINT PRESENTATION
Combined PI and NNRTI Resistance Analysis of the Pooled DUET Trial:
Towards a Regimen-Based
Resistance Interpretation
JM Schapiro, J Vingerhoets, S Nijs, et al
Slide Presentation
15th Conference on
Retroviruses and Opportunistic
Infections |
-
POSTER
Development of vircoTYPE HIV-1 Resistance Analysis, Including Clinical
Cutoffs for TMC125,
a New NNRTI
B Winters, J
Vingerhoets, M Peeters, et al
PDF Poster
Abstract-
POSTER
DUET-2: Week-48 Results of a Phase III Randomized Double-blind Trial to
Evaluate the Efficacy and
Safety of TMC125 vs Placebo in 591 Treatment-experienced HIV-1-infected
Patients
M Johnson, T
Campbell, B Clote, et al
PDF
Poster
Abstract -
POSTER
Pharmacokinetics and Pharmacodynamics of the NNRTI TMC125 in
Treatment-experienced HIV-1-infected
Patients: Pooled 24-week Results of DUET-1 and DUET-2
T Kakuda, J Wade E
Snoeck, et al
PDF
Poster
Abstract -
POSTER
Pharmacokinetics of the
Next-generation NNRTI TMC125 in HIV-infected Children between 6 and
17 Years of Age
T Kakuda, C Konigs, C
Feiterna-Sperling, et al
PDF Poster
Abstract-
POSTER
Prevalence of Mutations with Effect on Virological Response to
Etravirine in Routine Clinical Samples
J Llibre, J Santos,
T Puig,, et al
PDF Poster
Abstract -
Etravirine-resistance Mutations in Patients with Virologic Failure on
Nevirapine or
Efavirenz-based HAART
B
Taiwo, B Chaplin, J Stanton, et al
Abstract-
POSTER
Evaluating the Role of Etravirine in the Second-line ART after Failing
an Initial NNRTI-based
Regimens in a Resource-limited Setting
S Sungkanuparph, W
Manosuthi, S Kiertiburanakul, et al
PDF Poster
Abstract
-
POSTER
Pooled 24-week results of DUET-1 and DUET-2: efficacy of TMC125 (etravirine;
ETR) in treatment-experienced HIV-1-infected patients
C Katlama, JM Gatell, JM Molina, et al
PDF Poster
-
POSTER
Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine; ETR) safety
and tolerability in treatment-experienced, HIV-1-infected patients
G Di Perri, PM Girard, N Clumeck, et al
PDF Poster
-
POSTER
Impact of baseline NNRTI mutations on the virological response to TMC125
(etravirine; ETR) in the DUET-1 and DUET-2 Phase III clinical trials
J Vingerhoets, B Clotet, M Peeters , et al
PDF Poster
-
POSTER
Impact of TMC125, a next-generation NNRTI, on clinical outcomes (AIDS-defining
illnesses
and deaths): 24-week findings from a planned pooled analysis of the DUET studies
J Gatell, G Beatty, M Johnson, et al
PDF Poster
-
POSTER
No pharmacokinetic interaction between TMC125(etravirine; ETR) and paroxetine
in HIV-negative volunteers
M Schöller-Gyüre, TN Kakuda, S Bollen, et al
PDF Poster
-
POSTER
Thorough QT trial with TMC125 (etravirine; ETR) dosed at200mg bid and 400mg qd
in HIV-negative
volunteers
M Peeters, K Janssen, G De Smedt, et al
PDF Poster
The American
Conference for the Treatment of HIV- 2007
|
TMC125 in Combination With Medications Commonly Used in HIV
Infection:
Summary of Drug-Drug Interactions
T Surles, M Schöller-Gyüre, RM
Hoetelmans, et al
PDF Poster
POSTER
Development of a list of mutations associated with NNRTI resistance for use in
clinical research
L Tambuyzer, J Vingerhoets, H Azijn, et al
PDF Poster
|
Etravirine Conference Citations |
|
6th
IAS Conference
Conference
Archives
Etravirine
Main Page